FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stephen Whitehead

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Dengue

Physiology

Virus Replication

Anatomy

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Ebenezer Tumban; Stephen S Whitehead; Katherine I Young; Christopher T Hanson; Nyree E Maes; Erin E Schirtzinger; Kathryn A Hanley
Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.
Anna P Durbin; Daniel Elwood; Noreen A Hynes; Beth D Kirkpatrick; Catherine J Larsson; Janet C Lindow; Catherine J Luke; Brian R Murphy; Kristen K Pierce; Beulah P Sabundayo; Donna Shaffer; Kanta Subbarao; KAWSAR TALAAT; Cecilia Tibery; Kimberli Wanionek; Marya P Carmolli; Stephen S Whitehead
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
Anna P Durbin; Stephen S Whitehead
The dengue human challenge model: has the time come to accept this challenge?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stephen Whitehead (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ebenezer Tumban; Stephen S Whitehead; Katherine I Young; Christopher T Hanson; Nyree E Maes; Erin E Schirtzinger; Kathryn A Hanley
Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.
The Journal of general virology 2013;94(Pt 4):783-8.
2013: Anna P Durbin; Daniel Elwood; Noreen A Hynes; Beth D Kirkpatrick; Catherine J Larsson; Janet C Lindow; Catherine J Luke; Brian R Murphy; Kristen K Pierce; Beulah P Sabundayo; Donna Shaffer; Kanta Subbarao; KAWSAR TALAAT; Cecilia Tibery; Kimberli Wanionek; Marya P Carmolli; Stephen S Whitehead
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
The Journal of infectious diseases 2013;207(6):957-65.
2013: Anna P Durbin; Stephen S Whitehead
The dengue human challenge model: has the time come to accept this challenge?
The Journal of infectious diseases 2013;207(5):697-9.
2012: Tsai-Yu Lin; Carolyn J Manhart; Steevenson Nelson; Kimberly A Dowd; Stephen S Whitehead; Theodore C Pierson
A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus.
Journal of virology 2012;86(7):3501-12.
2012: Janet C Lindow; Stephen S Whitehead; Nathan Borochoff-Porte; Janice Y Bunn; Anna P Durbin; Kelly A Fimlaid; Beth D Kirkpatrick
Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.
PLoS neglected tropical diseases 2012;6(7):e1742.
2011: Anna P Durbin; Stephen S Whitehead
Next-generation dengue vaccines: novel strategies currently under development.
Viruses 2011;3(10):1800-14.
2011: Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.
Vaccine 2011;29(42):7242-50.
2011: Anna P Durbin; Dan Elwood; Brian R Murphy; Donna Shaffer; Bhagvanji Thumar; Kimberli Wanionek; Stephen S Whitehead; Joseph E Blaney; Alexander C Schmidt
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
PLoS neglected tropical diseases 2011;5(8):e1267.
2011: Kimberly A Dowd; Anna P Durbin; Christiane A Jost; Stephen S Whitehead; Theodore C Pierson
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.
PLoS pathogens 2011;7(6):e1002111.
2011: Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhagvanji Thumar; Brian R Murphy; Stephen S Whitehead
Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.
The Journal of infectious diseases 2011;203(3):327-34.
2011: Richard G Bennett; Jacob T Nelson; Anthony K Gresko; Brian R Murphy; Stephen S Whitehead
The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys.
Virology journal 2011;8():136.
2011: Richard G Bennett; Anthony K Gresko; Brian R Murphy; Stephen S Whitehead
Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys.
Virology journal 2011;8():135.
2011: Brian R Murphy; Stephen S Whitehead
Immune response to dengue virus and prospects for a vaccine.
Annual review of immunology 2011;29():587-619.
2010: Joseph E Blaney; Anna P Durbin; Brian R Murphy; Stephen S Whitehead
Targeted mutagenesis as a rational approach to dengue virus vaccine development.
Current topics in microbiology and immunology 2010;338():145-58.
2010: Anna P Durbin; Stephen S Whitehead
Dengue vaccine candidates in development.
Current topics in microbiology and immunology 2010;338():129-43.
2009: Peter F Wright; Anna P Durbin; Stephen S Whitehead; Mine R Ikizler; Susan Henderson; Joseph E Blaney; Bhagvanji Thumar; Sharon Ankrah; Michael T Rock; Brett A McKinney; Brian R Murphy; Alexander C Schmidt
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
The American journal of tropical medicine and hygiene 2009;81(5):834-41.
2008: Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhagvanji Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian Murphy; Stephen S Whitehead
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
The American journal of tropical medicine and hygiene 2008;79(5):678-84.
2008: Joseph E Blaney; Jim Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian Murphy; Alexander G Pletnev
Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.
Vaccine 2008;26(33):4150-9.
2008: Peter F Wright; Sharon Ankrah; Susan E Henderson; Anna P Durbin; Jim Speicher; Stephen S Whitehead; Brian Murphy; Alexander G Pletnev
Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
Vaccine 2008;26(7):882-90.
2008: Joseph E Blaney; Neeraj S Sathe; Laura B Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Vaccine 2008;26(6):817-28.
2008: Richard G Bennett; Christina M Cress; Jerrold M Ward; Cai-Yen Firestone; Brian Murphy; Stephen S Whitehead
La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys.
Virology journal 2008;5():25.
2007: Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian Murphy
Prospects for a dengue virus vaccine.
Nature reviews. Microbiology 2007;5(7):518-28.
2007: Richard G Bennett; David R Ton; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes.
Virology journal 2007;4():41.
2007: Joseph E Blaney; Neeraj S Sathe; Christopher T Hanson; Cai-Yen Firestone; Brian Murphy; Stephen S Whitehead
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Virology journal 2007;4():23.
2006: Anna P Durbin; Julie H McArthur; Jennifer A Marron; Joseph E Blaney; Bhagvanji Thumar; Kimberli Wanionek; Brian Murphy; Stephen S Whitehead
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
Human vaccines 2006;2(6):255-60.
2006: Anna P Durbin; Julie H McArthur; Jennifer A Marron; Joseph E Blaney; Bhagvanji Thumar; Kim Wanionek; Brian Murphy; Stephen S Whitehead
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Human vaccines 2006;2(4):167-73.
2006: Joseph E Blaney; Anna P Durbin; Brian Murphy; Stephen S Whitehead
Development of a live attenuated dengue virus vaccine using reverse genetics.
Viral immunology 2006;19(1):10-32.
2005: Joseph E Blaney; Jennifer M Matro; Brian Murphy; Stephen S Whitehead
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Journal of virology 2005;79(9):5516-28.
2005: Anna P Durbin; Stephen S Whitehead; Julie H McArthur; John R Perreault; Joseph E Blaney; Bhagvanji Thumar; Brian Murphy; Ruth A Karron
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
The Journal of infectious diseases 2005;191(5):710-8.
2004: Joseph E Blaney; Christopher T Hanson; Cai-Yen Firestone; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
The American journal of tropical medicine and hygiene 2004;71(6):811-21.
2004: Joseph E Blaney; Christopher T Hanson; Kathryn A Hanley; Brian Murphy; Stephen S Whitehead
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
BMC infectious diseases 2004;4():39.
2004: Kathryn A Hanley; Luella R Manlucu; Gracielle G Manipon; Christopher T Hanson; Stephen S Whitehead; Brian Murphy; Joseph E Blaney
Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Vaccine 2004;22(25-26):3440-8.
2004: Brian Murphy; Joseph E Blaney; Stephen S Whitehead
Arguments for live flavivirus vaccines.
Lancet 2004;364(9433):499-500.
2003: Joseph E Blaney; Gracielle G Manipon; Cai-Yen Firestone; Daniel H Johnson; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.
Vaccine 2003;21(27-30):4317-27.
2003: Stephen S Whitehead; Kathryn A Hanley; Joseph E Blaney; Lara E Gilmore; William R Elkins; Brian Murphy
Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Vaccine 2003;21(27-30):4307-16.
2003: Kathryn A Hanley; Luella R Manlucu; Lara E Gilmore; Joseph E Blaney; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.
Virology 2003;312(1):222-32.
2003: Joseph E Blaney; Gracielle G Manipon; Brian Murphy; Stephen S Whitehead
Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice.
Archives of virology 2003;148(5):999-1006.
2003: Stephen S Whitehead; Barry Falgout; Kathryn A Hanley; Joseph E Blaney Jr; Lewis Markoff; Brian Murphy
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
Journal of virology 2003;77(2):1653-7.
2002: Joseph E Blaney; Daniel H Johnson; Gracielle G Manipon; Cai-Yen Firestone; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.
Virology 2002;300(1):125-39.
2002: Kathryn A Hanley; Jay J Lee; Joseph E Blaney; Brian Murphy; Stephen S Whitehead
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.
Journal of virology 2002;76(2):525-31.
2001: J M Troyer; Kathryn A Hanley; Stephen S Whitehead; Daniel Strickman; Ruth A Karron; Anna P Durbin; Brian Murphy
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
The American journal of tropical medicine and hygiene 2001;65(5):414-9.
2001: Anna P Durbin; Ruth A Karron; W Sun; D W Vaughn; M J Reynolds; John R Perreault; Bhagvanji Thumar; Ruhe Men; Ching-Juh Lai; William R Elkins; Robert M Chanock; Brian Murphy; Stephen S Whitehead
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
The American journal of tropical medicine and hygiene 2001;65(5):405-13.
2001: Michael N Teng; Stephen S Whitehead; Peter L Collins
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Virology 2001;289(2):283-96.
2001: Joseph E Blaney; Daniel H Johnson; Cai-Yen Firestone; Christopher T Hanson; Brian Murphy; Stephen S Whitehead
Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Journal of virology 2001;75(20):9731-40.
2000: Peter F Wright; Ruth A Karron; Robert B Belshe; Juliette Thompson; James Crowe; Thomas G Boyce; L L Halburnt; George W Reed; Stephen S Whitehead; Edwin L Anderson; A E Wittek; Roberta Casey; Maryna C Eichelberger; Bhagvanji Thumar; Valerie B Randolph; Stephen A Udem; Robert M Chanock; Brian Murphy
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
The Journal of infectious diseases 2000;182(5):1331-42.
2000: Michael N Teng; Stephen S Whitehead; Alison Bermingham; Marisa St Claire; William R Elkins; Brian Murphy; Peter L Collins
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.
Journal of virology 2000;74(19):9317-21.
2000: Alexander Bukreyev; Stephen S Whitehead; C Prussin; Brian Murphy; Peter L Collins
Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.
Journal of virology 2000;74(15):7151-7.
1999: Stephen S Whitehead; M G Hill; Cai-Yen Firestone; Marisa St Claire; William R Elkins; Brian Murphy; Peter L Collins
Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
Journal of virology 1999;73(12):9773-80.
1999: Stephen S Whitehead; Alexander Bukreyev; Michael N Teng; Cai-Yen Firestone; Marisa St Claire; William R Elkins; Peter L Collins; Brian Murphy
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
Journal of virology 1999;73(4):3438-42.
1999: K Juhasz; Stephen S Whitehead; C A Boulanger; Cai-Yen Firestone; Peter L Collins; Brian Murphy
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
Vaccine 1999;17(11-12):1416-24.
1999: Alexander Bukreyev; Stephen S Whitehead; N Bukreyeva; Brian Murphy; Peter L Collins
Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2367-72.
1999: Stephen S Whitehead; Cai-Yen Firestone; Ruth A Karron; James Crowe; William R Elkins; Peter L Collins; Brian Murphy
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
Journal of virology 1999;73(2):871-7.
1999: Peter L Collins; Stephen S Whitehead; Alexander Bukreyev; Rachel Fearns; Michael N Teng; K Juhasz; Robert M Chanock; Brian Murphy
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.
Advances in virus research 1999;54():423-51.
1998: Stephen S Whitehead; Cai-Yen Firestone; Peter L Collins; Brian Murphy
A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
Virology 1998;247(2):232-9.
1998: Stephen S Whitehead; K Juhasz; Cai-Yen Firestone; Peter L Collins; Brian Murphy
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.
Journal of virology 1998;72(5):4467-71.
1998: T Tao; Anna P Durbin; Stephen S Whitehead; F Davoodi; Peter L Collins; Brian Murphy
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Journal of virology 1998;72(4):2955-61.
1997: Ruth A Karron; Deborah A Buonagurio; A F Georgiu; Stephen S Whitehead; J E Adamus; Mary Lou Clements-Mann; D O Harris; Valerie B Randolph; Stephen A Udem; Brian Murphy; Maninder Sidhu
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(25):13961-6.
1997: Alexander Bukreyev; Stephen S Whitehead; Brian Murphy; Peter L Collins
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
Journal of virology 1997;71(12):8973-82.
1997: Anna P Durbin; S L Hall; JW Siew; Stephen S Whitehead; Peter L Collins; Brian Murphy
Recovery of infectious human parainfluenza virus type 3 from cDNA.
Virology 1997;235(2):323-32.
1997: K Juhasz; Stephen S Whitehead; P T Bui; J M Biggs; James Crowe; C A Boulanger; Peter L Collins; Brian Murphy
The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.
Journal of virology 1997;71(8):5814-9.
1996: Cai-Yen Firestone; Stephen S Whitehead; Peter L Collins; Brian Murphy; James Crowe
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
Virology 1996;225(2):419-22.
1996: James Crowe; Cai-Yen Firestone; Stephen S Whitehead; Peter L Collins; Brian Murphy
Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.
Virus genes 1996;13(3):269-73.